公开(公告)号：US09153367B2

公开(公告)日：2015-10-06

申请号：US13987912

申请日：2013-09-16

Applicant: Leisha M. Armijo

Inventor： Leisha M. Armijo

IPC: H01F1/01 ,  H01F1/06 ,  H01F1/00

CPC classification number: H01F1/01 ,  H01F1/0045 ,  H01F1/065

Abstract: Magnetic iron nitride nanoparticles, such as Fe16N2 nanoparticles, are made by subjecting iron nanoparticles synthesized from iron oxide or iron carbonyl precursor to a solid-gas reaction with a nitrogen-containing gas.

Abstract translation: 通过使由铁氧化物或羰基铁前体合成的铁纳米颗粒与含氮气体进行固体气体反应来制备磁性氮化铁纳米颗粒，例如Fe 16 N 2纳米颗粒。

公开(公告)号：US09125899B1

公开(公告)日：2015-09-08

申请号：US13161766

申请日：2011-06-16

Applicant: Angela-Wandinger Ness ,  Laurie Hudson ,  Larry Sklar ,  Zurab Surviladze ,  Tudor Oprea

Inventor： Angela-Wandinger Ness ,  Laurie Hudson ,  Larry Sklar ,  Zurab Surviladze ,  Tudor Oprea

IPC: A61K31/403

CPC classification number: A61K31/407 ,  A61K31/403 ,  A61K31/415 ,  A61K45/06 ,  C07D231/06 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/573 ,  Y02A50/473 ,  Y02A50/486 ,  A61K2300/00

Abstract: The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the Ras-homologous (Rho) family of small GTPases (e.g. Rac, Cdc42 and Rho GTPases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-B cell lymphoma, where these GTPases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of Rho GTPases plays a pivotal role (Menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type 1), Huntington's disease and Alzheimer's disease) which are mediated through these proteins. Compounds according to the present invention may also be used as a therapy for the treatment of Entamoeba spp. or Acanthamoeba spp, infections, especially including Entamoeba histolytica.

Abstract translation: 本发明涉及用作小GTP酶（例如Rac，Cdc42和Rho GTP酶）的Ras同源（Rho）家族的调节剂（即抑制剂和激动剂）的分子及其用于治疗疾病的用途，包括癌症（包括固体 肿瘤 - 成神经管细胞瘤，卵巢癌，乳腺癌，头颈部，睾丸癌，前列腺癌和血液恶性肿瘤--B细胞淋巴瘤，其中这些GTP酶过度表达或过度活化），其中Rho GTP酶的活化起关键作用的散发性和遗传性疾病（Menkes disease ，类风湿性关节炎，动脉粥样硬化，糖尿病（1型），亨廷顿氏病和阿尔茨海默氏病）。 根据本发明的化合物也可以用作治疗阿米巴疫霉的疗法。 或Acanthamoeba spp，感染，特别是包括溶组织内阿米巴（Entamoeba histolytica）。

公开(公告)号：US09068172B2

公开(公告)日：2015-06-30

申请号：US13823856

申请日：2011-09-15

Applicant: Surojit Paul

Inventor： Surojit Paul

IPC: C07K14/47 ,  C07K19/00 ,  A61K38/17 ,  A61P25/00 ,  C12N9/16 ,  A61K38/00

CPC classification number: C12N9/16 ,  A61K38/00 ,  A61K38/465 ,  C12Y301/03048

Abstract: A novel peptide sequence that is a modified derivative of a neuron-specific tyrosine phosphatase is shown and described. Specifically, the novel peptide sequence is a modified derivative of striatal-enriched tyrosine phosphatase (STEP). The peptide sequence has been modified so as to be able to ameliorate and treat brain injury resulting from excessive glutamate release and/or oxidative stress. Examples of the types of brain injury which the presently disclosed peptide sequence is useful for treating includes acute brain injury resulting from stroke or traumatic brain injury and chronic disorders such as Huntington's chorea and schizophrenia. Furthermore, the presently described peptide sequence may further be useful in the treatment and amelioration of disorders associated with fear memory such as post-traumatic stress disorder.

Abstract translation: 显示和描述了作为神经元特异性酪氨酸磷酸酶的修饰衍生物的新型肽序列。 具体来说，新肽序列是纹状体富含酪氨酸磷酸酶的修饰衍生物（STEP）。 肽序列已被修饰，以便能够改善和治疗由过量的谷氨酸释放和/或氧化应激引起的脑损伤。 目前公开的肽序列可用于治疗的脑损伤类型的实例包括由中风或创伤性脑损伤引起的急性脑损伤和慢性疾病如亨廷顿氏舞蹈症和精神分裂症。 此外，目前描述的肽序列还可用于治疗和改善与恐惧记忆相关的疾病，例如创伤后应激障碍。

公开(公告)号：US08962512B1

公开(公告)日：2015-02-24

申请号：US13344462

申请日：2012-01-05

Applicant: Patrick David Burton ,  Timothy J Boyle ,  Abhaya Datye

Inventor： Patrick David Burton ,  Timothy J Boyle ,  Abhaya Datye

IPC: B01J21/18 ,  B01J23/00 ,  B82Y30/00 ,  B01J23/44

CPC classification number: B01J21/18 ,  B01J23/44 ,  B01J35/0013 ,  B01J35/006 ,  B01J37/0063 ,  B82Y30/00 ,  B82Y40/00

Abstract: The present disclosure provides a novel synthesis method for palladium nanoparticles and palladium nanoparticles made using the method. The nanoparticles resulting from the method are highly reactive and, when deposited on a support, are highly suitable for use as catalytic material.

Abstract translation: 本公开提供了使用该方法制备的钯纳米颗粒和钯纳米颗粒的新型合成方法。 由该方法得到的纳米颗粒是高度反应性的，当沉积在载体上时，非常适合用作催化材料。

公开(公告)号：US20150010475A1

公开(公告)日：2015-01-08

申请号：US14369741

申请日：2012-12-31

Applicant: STC. UNM ,  SANDIA CORPORATION

Inventor： C. Jeffrey Brinker ,  David S. Peabody ,  Walker Kip Wharton ,  Bryce Chackerian ,  Carlee Erin Ashley ,  Cheryl L. Willman ,  Eric C. Carnes ,  Katherine Epler ,  Robert Eric Castillo

IPC: A61K47/48 ,  C12N15/113 ,  C12N15/11 ,  C07K7/06 ,  A61K31/704

CPC classification number: A61K31/704 ,  A61K47/62 ,  A61K47/64 ,  A61K47/6911 ,  C07K7/06 ,  C12N15/111 ,  C12N15/113

Abstract: The present invention relates to the use of which are attached or anchored phospholipid biolayers further modified by CRLF-2 and CD 19 binding peptides which may be used for delivering pharmaceutical cargos, to cells expressing CRLF-2 and CD 19, thereby treating cancer, in particular, acute lymphoblastic leukemia (ALL), including (B-precursor acute lymphoblastic leukemia (B-ALL). Novel CRLF-2 binding peptides and CLRF-2 and CD19-binding viral-like particles (VLPs) useful in the treatment of cancer, including ALL are also provided.

Abstract translation: 本发明涉及其用途，其可用于将可用于递送药物载体的CRLF-2和CD19结合肽进一步修饰的磷脂生物层结合到表达CRLF-2和CD19的细胞中，从而治疗癌症 特别是急性淋巴细胞白血病（ALL），包括（B-前体急性成淋巴细胞白血病（B-ALL）），用于治疗癌症的新型CRLF-2结合肽和CLRF-2和CD19结合病毒样颗粒（VLP） ，也包括ALL。

公开(公告)号：US08920382B1

公开(公告)日：2014-12-30

申请号：US13815405

申请日：2013-02-28

Applicant: Mark Hauswald

Inventor： Mark Hauswald

IPC: A61M5/178 ,  A61M5/315

CPC classification number: A61M5/3158 ,  A61M5/141 ,  A61M5/14216 ,  A61M5/1424 ,  A61M5/3148 ,  A61M5/31535 ,  A61M2005/1405 ,  A61M2005/3115 ,  A61M2202/048

Abstract: A mechanical patient-controlled analgesia device for injecting medicine into a patient's IV, includes an IV reservoir and a syringe communicated to the IV reservoir and having a syringe plunger. A mechanical biasing element is provided for exerting bias on the syringe plunger in a first syringe-filling direction to draw medicine from the IV reservoir into the syringe. An injection plunger is operable by the patient to move the syringe plunger in a second injection direction against the bias to inject the medicine in the syringe into a patient's IV. The injection plunger is movable independently of the syringe plunger and is engaged with but unconnected to the syringe plunger when the patient moves the injection plunger to inject the medicine. The patient can inject only a calibrated amount of medicine drawn into the syringe as determined by calibration of the biasing element and a metering element for a given viscosity of the medication.

Abstract translation: 用于将药物注射到患者IV中的机械患者控制的止痛装置包括连接到IV储液器并具有注射器柱塞的IV储液器和注射器。 提供了一种机械偏置元件，用于在第一注射器填充方向上在注射器柱塞上施加偏压，以将药物从IV储液器吸入注射器。 注射柱塞可由患者操作，以抵抗偏压在第二注射方向上移动注射器柱塞，以将注射器中的药物注入患者体内。 注射柱塞可以独立于针筒柱塞移动，并且当患者移动注射柱塞以注射药物时，注射柱塞可以与注射器柱塞接合但不连接。 患者可以仅注射被注入注射器中的校准量的药物，其通过偏置元件的校准和用于给定粘度的药物的计量元件来确定。

公开(公告)号：US08889689B2

公开(公告)日：2014-11-18

申请号：US13574941

申请日：2011-01-26

Applicant: Robert Hromas ,  Andrei Leitao ,  Tudor I. Oprea ,  Larry A. Sklar ,  Elizabeth A. Williamson ,  Justin Wray ,  Wei Wang

Inventor： Robert Hromas ,  Andrei Leitao ,  Tudor I. Oprea ,  Larry A. Sklar ,  Elizabeth A. Williamson ,  Justin Wray ,  Wei Wang

IPC: A61K31/497 ,  A61K45/06 ,  C07D401/12 ,  C07D215/56 ,  A61K31/4709 ,  A61K31/47

CPC classification number: C07D215/56 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/475 ,  A61K31/496 ,  A61K31/7048 ,  A61K45/06 ,  A61N5/1001 ,  A61N5/1045 ,  A61N2005/1087 ,  A61N2005/1098 ,  C07D401/06 ,  C07D401/10 ,  C07D401/12 ,  A61K2300/00

Abstract: This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-I) that simultaneously damage DNA, and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols, including radiation therapy. In preferred embodiments, compounds, compositions and methods of treatment of the invention are used to treat a patient suffering from leukemia (e.g. acute myeloid leukemia (AML) and related cancers. In certain aspects of such treatments, compounds, compositions and methods of treatment of the invention are administered as a monotherapy (in some cases, to patients who have exhibited resistance to Topo IIalpha inhibitors such as VP-16), or are co-administered with a Topo IIalpha inhibitor or other anti-cancer agents as otherwise described herein or in combination with radiation therapy.

Abstract translation: 本发明涉及新的癌症治疗组合物和相关的治疗方法。 更具体地说，本发明部分涉及同时损伤DNA的DNA复制和修复蛋白质Metnase和/或Intnase（也称为Gypsy整合酶，Gypsy Integrease-1，Gypsy Retransposon Integrase 1或GIN-1）的小型化学双功能抑制剂， 以及利用抑制剂增加包括放射治疗在内的癌症治疗方案的有效性的治疗方法。 在优选的实施方案中，本发明的化合物，组合物和治疗方法用于治疗患有白血病的患者（例如急性骨髓性白血病（AML）和相关的癌症）。在这些治疗的某些方面，化合物，组合物和治疗方法 本发明作为单一疗法（在某些情况下，对已显示出对Topo IIalpha抑制剂如VP-16具有抗性的患者）施用，或者与本文另有描述的Topo IIal抑制剂或其它抗癌剂共同施用，或 结合放射治疗。

公开(公告)号：US08886283B1

公开(公告)日：2014-11-11

申请号：US13526210

申请日：2012-06-18

Applicant: Zikuan Chen ,  Vince D. Calhoun

Inventor： Zikuan Chen ,  Vince D. Calhoun

IPC: A61B5/055

CPC classification number: A61B5/4064 ,  A61B5/055 ,  A61B5/7246 ,  A61B5/7257 ,  A61B2576/026

Abstract: Magnetic susceptibility is the physical property for T2*-weighted magnetic resonance imaging (T2*MRI). The invention relates to methods for reconstructing an internal distribution (3D map) of magnetic susceptibility values, χ (x,y,z), of an object, from 3D T2*MRI phase images, by using Computed Inverse Magnetic Resonance Imaging (CIMRI) tomography. The CIMRI technique solves the inverse problem of the 3D convolution by executing a 3D Total Variation (TV) regularized iterative convolution scheme, using a split Bregman iteration algorithm. The reconstruction of χ (x,y,z) can be designed for low-pass, band-pass, and high-pass features by using a convolution kernel that is modified from the standard dipole kernel. Multiple reconstructions can be implemented in parallel, and averaging the reconstructions can suppress noise. 4D dynamic magnetic susceptibility tomography can be implemented by reconstructing a 3D susceptibility volume from a 3D phase volume by performing 3D CIMRI magnetic susceptibility tomography at each snapshot time.

Abstract translation: 磁化率是T2 *加权磁共振成像（T2 * MRI）的物理性质。 本发明涉及通过使用计算反向磁共振成像（CIMRI）从3D T2 * MRI相位图像重建物体的磁化率值（x，y，z）的内部分布（3D映射）的方法， 层析成像。 CIMRI技术通过使用分割Bregman迭代算法执行3D总变异（TV）正则化迭代卷积方案来解决3D卷积的逆问题。 χ（x，y，z）的重建可以通过使用从标准偶极子内核修改的卷积核心来设计用于低通，带通和高通特征。 可以并行实现多重重建，平均重建可以抑制噪声。 4D动态磁化率层析成像可以通过在每个快照时间通过执行3D CIMRI磁化率层析成像从3D相位体积重建3D磁化率体积来实现。

公开(公告)号：US20140323292A1

公开(公告)日：2014-10-30

申请号：US14359087

申请日：2012-11-21

Applicant: STC.UNM

Inventor： Claudia Catalina Luhrs ,  Eric Brosha ,  Jonathan Phillips

IPC: B01J23/42 ,  B01J21/04 ,  B01J21/18 ,  B01J21/06

CPC classification number: B01J23/42 ,  B01J21/04 ,  B01J21/063 ,  B01J21/18 ,  B01J23/44 ,  B01J23/745 ,  B01J23/755 ,  B01J35/002 ,  B01J35/006 ,  B01J35/0093 ,  B01J35/1014 ,  B01J35/1028 ,  B01J37/0036 ,  B01J37/04 ,  B01J37/16 ,  H01M4/88 ,  H01M4/8842 ,  H01M4/9041 ,  H01M4/925 ,  H01M4/926

Abstract: Provided is a method for making a supported metal catalyst. The method includes forming a mixture comprising a high surface area support, a reducing agent precursor that decomposes to produce reducing gases below about 1200° C., and a metal catalyst precursor. The mixture is heated to a temperature sufficient to decompose the reducing agent precursor to produce a reducing agent, and then cooled to form the supported metal catalyst.

Abstract translation: 提供一种制备负载型金属催化剂的方法。 该方法包括形成包含高表面积载体，分解产生低于约1200℃的还原气体的还原剂前体和金属催化剂前体的混合物。 将混合物加热到足以分解还原剂前体以产生还原剂的温度，然后冷却以形成负载的金属催化剂。

公开(公告)号：US08871483B1

公开(公告)日：2014-10-28

申请号：US14136269

申请日：2013-12-20

Applicant: Plamen B Atanassov ,  Claudia W Narvaez Villarrubia ,  Sofiya Malinova Babanova

Inventor： Plamen B Atanassov ,  Claudia W Narvaez Villarrubia ,  Sofiya Malinova Babanova

IPC: C12N11/06 ,  H01M4/90

CPC classification number: H01M4/9008 ,  B82Y5/00 ,  C12N9/0006 ,  C12N9/001 ,  C12N9/0057 ,  C12N11/14 ,  C12Y101/05002 ,  C12Y103/03005 ,  C12Y110/03002

Abstract: The present disclosure provides multi-walled carbon nanotubes and carbon nanotubes (CNTs) displaying catalytic enzymes bound to the nanotube sidewalls and devices, such as electrodes, incorporating these catalytic enzyme-bound CNTs (cebCNTs).

Abstract translation: 本公开提供了多壁碳纳米管和碳纳米管（CNT），其显示结合到纳米管侧壁的催化酶和包含这些催化酶结合的CNT（cebCNT）的装置，例如电极）。